WO1995025509A2 - Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity - Google Patents
Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity Download PDFInfo
- Publication number
- WO1995025509A2 WO1995025509A2 PCT/EP1995/001002 EP9501002W WO9525509A2 WO 1995025509 A2 WO1995025509 A2 WO 1995025509A2 EP 9501002 W EP9501002 W EP 9501002W WO 9525509 A2 WO9525509 A2 WO 9525509A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- acid
- group
- pharmaceutical compositions
- aromatic
- Prior art date
Links
- 230000003492 excitotoxic Effects 0.000 title claims description 13
- 231100000063 excitotoxicity Toxicity 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title description 3
- 230000002981 neuropathic Effects 0.000 title description 3
- 230000000324 neuroprotective Effects 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 150000001991 dicarboxylic acids Chemical class 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims description 20
- -1 unsaturated aliphatic monocarboxylic acid Chemical class 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 15
- 125000001931 aliphatic group Chemical group 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- LVTYICIALWPMFW-UHFFFAOYSA-N 1-(2-hydroxypropylamino)propan-2-ol Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 claims description 6
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-Amino-2-propanol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 6
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 5
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 208000001183 Brain Injury Diseases 0.000 claims description 5
- 206010008748 Chorea Diseases 0.000 claims description 5
- 206010015037 Epilepsy Diseases 0.000 claims description 5
- 208000009025 Nervous System Disease Diseases 0.000 claims description 5
- 208000008513 Spinal Cord Injury Diseases 0.000 claims description 5
- 206010044390 Transient ischaemic attack Diseases 0.000 claims description 5
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 5
- 201000001973 choreatic disease Diseases 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 3
- 210000001525 Retina Anatomy 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- MAZWDMBCPDUFDJ-VQHVLOKHSA-N Traumatic acid Chemical compound OC(=O)CCCCCCCC\C=C\C(O)=O MAZWDMBCPDUFDJ-VQHVLOKHSA-N 0.000 claims description 3
- 208000001756 Virus Disease Diseases 0.000 claims description 3
- 230000001476 alcoholic Effects 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 125000005027 hydroxyaryl group Chemical group 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 230000000302 ischemic Effects 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 230000003287 optical Effects 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 229960005261 Aspartic Acid Drugs 0.000 claims description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003367 polycyclic group Chemical group 0.000 claims description 2
- 229960001367 tartaric acid Drugs 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 206010029305 Neurological disorder Diseases 0.000 claims 2
- 206010047461 Viral infection Diseases 0.000 claims 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 1
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 claims 1
- 230000002461 excitatory amino acid Effects 0.000 abstract description 10
- 239000003257 excitatory amino acid Substances 0.000 abstract description 10
- 150000002763 monocarboxylic acids Chemical class 0.000 abstract description 5
- 230000002035 prolonged Effects 0.000 abstract description 3
- 230000005284 excitation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- HXYVTAGFYLMHSO-UHFFFAOYSA-M CCCCCCCCCCCCCCCC(=O)[N-]CCO Chemical compound CCCCCCCCCCCCCCCC(=O)[N-]CCO HXYVTAGFYLMHSO-UHFFFAOYSA-M 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000000138 Mast Cells Anatomy 0.000 description 8
- 230000001154 acute Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 230000001684 chronic Effects 0.000 description 7
- 231100000318 excitotoxic Toxicity 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 150000001414 amino alcohols Chemical class 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001537 neural Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- PAHZPHDAJQIETD-UHFFFAOYSA-N Adelmidrol Chemical compound OCCNC(=O)CCCCCCCC(=O)NCCO PAHZPHDAJQIETD-UHFFFAOYSA-N 0.000 description 5
- LGEQQWMQCRIYKG-DOFZRALJSA-N Anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 5
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 description 5
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000002887 neurotoxic Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010061536 Parkinson's disease Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000001146 hypoxic Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001681 protective Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 206010053643 Neurodegenerative disease Diseases 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000002490 cerebral Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910001410 inorganic ion Inorganic materials 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 230000000926 neurological Effects 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N (Z,Z,Z)-Octadeca-9,12,15-trienoic acid Natural products CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 206010065040 AIDS dementia complex Diseases 0.000 description 2
- 229940040526 Anhydrous Sodium Acetate Drugs 0.000 description 2
- 229940114079 Arachidonic Acid Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- FSQSNFFVEJCHQQ-UHFFFAOYSA-M CC(=O)OCC[N-]C(=O)C1=CC=CC=C1 Chemical compound CC(=O)OCC[N-]C(=O)C1=CC=CC=C1 FSQSNFFVEJCHQQ-UHFFFAOYSA-M 0.000 description 2
- KNZOGQPUJYKSAA-UHFFFAOYSA-M CCCCCCCCCCCCCCCC(=O)[N-]CCOC(C)=O Chemical compound CCCCCCCCCCCCCCCC(=O)[N-]CCOC(C)=O KNZOGQPUJYKSAA-UHFFFAOYSA-M 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 208000005721 HIV Infections Diseases 0.000 description 2
- 206010020993 Hypoglycaemia Diseases 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- 210000001640 Nerve Endings Anatomy 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- KRTXMMPPGNHRJO-UHFFFAOYSA-N OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.OCCNC(=O)CCCCCCCCC=CC(=O)NCCO Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.OCCNC(=O)CCCCCCCCC=CC(=O)NCCO KRTXMMPPGNHRJO-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Octadecanoic acid Natural products CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N Phosphorus pentoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- MTCKBXHFHASTLA-UHFFFAOYSA-L [Na+].[Na+].OP(O)(=O)OP([O-])([O-])=O.OCCNC(=O)CCCCCCCCC=CC(=O)NCCO Chemical compound [Na+].[Na+].OP(O)(=O)OP([O-])([O-])=O.OCCNC(=O)CCCCCCCCC=CC(=O)NCCO MTCKBXHFHASTLA-UHFFFAOYSA-L 0.000 description 2
- GQPMAQDRMNNGCV-UHFFFAOYSA-K [O-]C(=O)CCC([O-])=O.CCCCCCCCCCCCCCCC(=O)[N-]CCO Chemical compound [O-]C(=O)CCC([O-])=O.CCCCCCCCCCCCCCCC(=O)[N-]CCO GQPMAQDRMNNGCV-UHFFFAOYSA-K 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000007098 aminolysis reaction Methods 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000003284 homeostatic Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052806 inorganic carbonate Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000000770 pro-inflamatory Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 200000000020 tissue injury Diseases 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 102000015404 Amino Acid Receptors Human genes 0.000 description 1
- 108010025177 Amino Acid Receptors Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 210000003792 Cranial Nerves Anatomy 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 210000003016 Hypothalamus Anatomy 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N Linoleic acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 Linolenic Acid Drugs 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 208000008585 Mastocytosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- KVEKZIRJMOWBAX-UHFFFAOYSA-N N,N'-bis(2-hydroxyethyl)dodec-2-enediamide Chemical compound OCCNC(=O)CCCCCCCCC=CC(=O)NCCO KVEKZIRJMOWBAX-UHFFFAOYSA-N 0.000 description 1
- ZKSYUNLBFSOENV-UHFFFAOYSA-M N-(2-hydroxyethyl)benzenecarboximidate Chemical compound OCC[N-]C(=O)C1=CC=CC=C1 ZKSYUNLBFSOENV-UHFFFAOYSA-M 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- HTKKEPZVJFWBOW-OWOJBTEDSA-L OCC[N-]C(=O)\C=C\C(=O)[N-]CCO Chemical compound OCC[N-]C(=O)\C=C\C(=O)[N-]CCO HTKKEPZVJFWBOW-OWOJBTEDSA-L 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- 102100018344 PRPF3 Human genes 0.000 description 1
- 101700055558 PRPF3 Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N Quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 101710005260 RPL6A Proteins 0.000 description 1
- 101710005264 RPL6B Proteins 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000003399 chemotactic Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000002964 excitative Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000000848 glutamatergic Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 230000002267 hypothalamic Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- XGZVLEAZGCUUPH-UHFFFAOYSA-N methylamino(methylimino)methanesulfonic acid Chemical compound CNC(=NC)S(O)(=O)=O XGZVLEAZGCUUPH-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 230000001272 neurogenic Effects 0.000 description 1
- 230000036963 noncompetitive Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000004983 pleiotropic Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002186243A CA2186243C (en) | 1994-03-21 | 1995-03-17 | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity |
| EP95928865A EP0804179B1 (en) | 1994-03-21 | 1995-03-17 | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity |
| JP7524371A JPH09510467A (ja) | 1994-03-21 | 1995-03-17 | 興奮毒性に関連した神経病理学的な状態において神経保護作用を行う薬剤の製造におけるアミノアルコールのｎ−アシル誘導体の使用 |
| AU21090/95A AU2109095A (en) | 1994-03-21 | 1995-03-17 | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity |
| DE69510825T DE69510825D1 (de) | 1994-03-21 | 1995-03-17 | Verwendung von n-acylderivaten aminoalcoholen zur herstellung eines medikamentes zum ausübung neuroprotektiver wirkung bei neuropathologischen mit excitotoxizität verbundenen zuständen |
| US08/714,113 US5925678A (en) | 1994-03-21 | 1995-03-17 | Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament for practicing neuroprotective action in neuropathological states connected with excitotoxicity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI94A000523 | 1994-03-21 | ||
| ITMI940523A IT1271623B (it) | 1994-03-21 | 1994-03-21 | N-acilderivati di aminoalcoli con acidi monocarbossilici e bicarbossilici con attivita' neuroprotettiva nelle patologie neurologiche correlate ad eccitotossicita' |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1995025509A2 true WO1995025509A2 (en) | 1995-09-28 |
| WO1995025509A3 WO1995025509A3 (en) | 1995-10-12 |
Family
ID=11368280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1995/001002 WO1995025509A2 (en) | 1994-03-21 | 1995-03-17 | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5925678A (und) |
| EP (1) | EP0804179B1 (und) |
| JP (1) | JPH09510467A (und) |
| AT (1) | AT182075T (und) |
| AU (1) | AU2109095A (und) |
| DE (1) | DE69510825D1 (und) |
| IT (1) | IT1271623B (und) |
| WO (1) | WO1995025509A2 (und) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996018391A2 (en) * | 1994-12-14 | 1996-06-20 | Lifegroup S.P.A. | Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| WO2002094302A1 (en) * | 2001-05-23 | 2002-11-28 | Gil-Ja Jhon | Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410597B1 (en) * | 2000-02-25 | 2002-06-25 | Virginia Commonwealth University | Hydroxyalkyl amide analogs of ceramide |
| US20030191064A1 (en) * | 2001-01-23 | 2003-10-09 | Kopke Richard D. | Methods for preventing and treating loss of balance function due to oxidative stress |
| ITMI20011483A1 (it) * | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| DE10351111A1 (de) * | 2003-11-03 | 2005-06-16 | Langlotz, Rainer | Arzneimittel und Verfahren zu ihrer Herstellung |
| CA3040258A1 (en) | 2016-10-13 | 2018-04-19 | Carnot, Llc | N-acylethanolamide derivatives and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0177245A2 (en) * | 1984-09-28 | 1986-04-09 | Nippon Chemiphar Co., Ltd. | Amino-alcohol derivatives and processes for their preparation |
| EP0550008A2 (en) * | 1991-12-31 | 1993-07-07 | LIFEGROUP S.p.A. | Use of N-acyl derivatives of aminoalcohols with polycarboxylic acids for the manufacture of a medicament for the treatment of pathologies relating to mast cells |
| US5227397A (en) * | 1989-04-28 | 1993-07-13 | Pfizer Inc. | Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels |
| EP0570714A2 (en) * | 1992-04-24 | 1993-11-24 | LIFEGROUP S.p.A. | Aminoalcohols-n-acylderivatives as therapeutical agents against the neurogenic endoneural oedema developing at the peripheral nerve |
| WO1993025203A1 (en) * | 1992-06-17 | 1993-12-23 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo[a,d]cyclohepten-5,10-imine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618842A (en) * | 1991-12-31 | 1997-04-08 | Lifegroup S.P.A. | N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin |
-
1994
- 1994-03-21 IT ITMI940523A patent/IT1271623B/it active IP Right Grant
-
1995
- 1995-03-17 US US08/714,113 patent/US5925678A/en not_active Expired - Lifetime
- 1995-03-17 JP JP7524371A patent/JPH09510467A/ja active Pending
- 1995-03-17 DE DE69510825T patent/DE69510825D1/de not_active Expired - Lifetime
- 1995-03-17 WO PCT/EP1995/001002 patent/WO1995025509A2/en active IP Right Grant
- 1995-03-17 AT AT95928865T patent/AT182075T/de unknown
- 1995-03-17 AU AU21090/95A patent/AU2109095A/en not_active Abandoned
- 1995-03-17 EP EP95928865A patent/EP0804179B1/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0177245A2 (en) * | 1984-09-28 | 1986-04-09 | Nippon Chemiphar Co., Ltd. | Amino-alcohol derivatives and processes for their preparation |
| US5227397A (en) * | 1989-04-28 | 1993-07-13 | Pfizer Inc. | Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels |
| EP0550008A2 (en) * | 1991-12-31 | 1993-07-07 | LIFEGROUP S.p.A. | Use of N-acyl derivatives of aminoalcohols with polycarboxylic acids for the manufacture of a medicament for the treatment of pathologies relating to mast cells |
| EP0570714A2 (en) * | 1992-04-24 | 1993-11-24 | LIFEGROUP S.p.A. | Aminoalcohols-n-acylderivatives as therapeutical agents against the neurogenic endoneural oedema developing at the peripheral nerve |
| WO1993025203A1 (en) * | 1992-06-17 | 1993-12-23 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo[a,d]cyclohepten-5,10-imine |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996018391A2 (en) * | 1994-12-14 | 1996-06-20 | Lifegroup S.P.A. | Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| WO1996018391A3 (en) * | 1994-12-14 | 1996-08-15 | Lifegroup Spa | Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| WO2002094302A1 (en) * | 2001-05-23 | 2002-11-28 | Gil-Ja Jhon | Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI940523A1 (it) | 1995-09-21 |
| AU2109095A (en) | 1995-10-09 |
| WO1995025509A3 (en) | 1995-10-12 |
| DE69510825D1 (de) | 1999-08-19 |
| EP0804179B1 (en) | 1999-07-14 |
| JPH09510467A (ja) | 1997-10-21 |
| IT1271623B (it) | 1997-06-04 |
| AT182075T (de) | 1999-07-15 |
| EP0804179A2 (en) | 1997-11-05 |
| ITMI940523D0 (it) | 1994-03-21 |
| US5925678A (en) | 1999-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0799188B1 (en) | Amides of mono and dicarboxylic acids with glycosamines, selectively active on the cannabinoid peripheral receptor | |
| US5506224A (en) | N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes | |
| JP4216330B2 (ja) | 末梢カンナビノイドレセプターで作用する薬物製造でのモノおよびビカルボン酸アミドの利用 | |
| KR100450498B1 (ko) | 레티노이드형생리활성을갖는치환아릴헤테로아릴라미드 | |
| KR20140030122A (ko) | 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴 | |
| CA2086442A1 (en) | N-acyl derivatives of aminoalcohols active as local autocoidis and useful in the therapy of autoimmune processes | |
| EP1615669A2 (en) | Peg-wortmannin conjugates | |
| EP1592418B1 (en) | Use of endocannabinoid-like compounds for treating cns degenerative disorders | |
| CN1974545B (zh) | 长链脂肪酰胺类化合物及其应用 | |
| EP0804179B1 (en) | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity | |
| US5618842A (en) | N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin | |
| JPH05339153A (ja) | アミノアルコールとポリカルボン酸とのｎ−アシル誘導体を含む医薬組成物 | |
| EP1972338A1 (en) | Anti-infective agents | |
| AU2017262155A1 (en) | Certain protein kinase inhibitors | |
| JP4063864B2 (ja) | 興奮性毒性に関連した中枢神経系の急性ならびに慢性障害に有用な、神経保護、神経栄養、ならびに抗炎症作用を有するｎ−アシルアルキルアミンのグルコシド誘導体 | |
| CN103384522B (zh) | 咖啡酸衍生物和它们在改善神经细胞生存力中的用途 | |
| CA2186243C (en) | Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity | |
| WO2013064714A1 (es) | Fármacos inhibidores de p38 y aplicaciones | |
| JP6426746B2 (ja) | ４−メチルスルホニル−２−ブテンニトリル及びその医薬上の使用 | |
| EP3048886B1 (en) | 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use | |
| EP0504180B1 (en) | Glycyl-p-amino-pyridine for the treatment of senile dementia states | |
| TWI535725B (zh) | 用以治療發炎和／或腫瘤的新穎倍半萜類化合物之衍生物及包含此新穎倍半萜類化合物之衍生物的組合物 | |
| KR20000053379A (ko) | 신규의 치환 알킬테트라아민 유도체 | |
| JPH10175962A (ja) | フェナジン ５−オキシド誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2186243 Country of ref document: CA Ref document number: 08714113 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1995928865 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1995928865 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1995928865 Country of ref document: EP |